2023
Impact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV
Hicks D, Salahuddin S, Wu M, Perez-Irizarry J, Emu B, Park H. Impact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e588. DOI: 10.1016/j.ijrobp.2023.06.1934.Peer-Reviewed Original ResearchCells/mm3CD4 countPercentage of baselineMann-Whitney testCD4 T-cell declineMedian baseline CD4 countMedian nadir CD4 countCancer treatmentBaseline CD4 countCancer treatment initiationMedian baseline CD4Treatment-related immunosuppressionNadir CD4 countMajority of patientsRetrospective chart reviewTime of diagnosisStart of treatmentT-cell declineNeck cancer treatmentMATERIAL/METHODSNonparametric Mann-Whitney testBaseline CD4Immunologic declineMedian CD4Antiretroviral therapy
2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang C, Yarchoan R, Cheever MA. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. JAMA Oncology 2019, 5: 1332-1339. PMID: 31154457, PMCID: PMC6547135, DOI: 10.1001/jamaoncol.2019.2244.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaSafety of pembrolizumabB-cell lymphoproliferationCells/μLAntiretroviral therapyTumor responseKaposi's sarcomaStable diseaseCD4 countAdverse eventsAdvanced cancerMost treatment-emergent adverse eventsAdverse Events grade 2Anti-PD-1 therapyNCI Common Terminology CriteriaTreatment-emergent adverse eventsActive immunosuppressive therapyCommon Terminology CriteriaGood tumor responseT-cell countsAlanine aminotransferase levelsHIV viral loadPhase 1 studyImmune-related eventsCopies/mL